Clinical Development Challenges: Failure to achieve positive clinical trial outcomes or demonstrate sufficient efficacy and safety for pipeline candidates:. Alnylam's extensive pipeline, including new indications for approved products and novel RNAi therapies, faces inherent risks of clinical trial failures, unexpected adverse events, or delays that could impact future revenue and stock performance.

Regulatory Approval Uncertainty: Inability to secure timely and broad regulatory approvals for new product candidates or expanded indications:. Despite promising clinical data, regulatory bodies like the FDA and EMA may not grant approval or may impose restrictions, requiring additional studies, which could delay or prevent market access for Alnylam's potential new drugs.

Competitive Landscape Pressure: Introduction of new competitive products or therapies by rival companies that may be more effective, safer, or cost-efficient:. Alnylam operates in highly competitive therapeutic areas, and the emergence of new treatments, including gene therapies, small molecules, or competing RNAi therapies from other companies, could limit the market share and sales of its existing and pipeline products.